Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

What Should be the Next Vasopressor for Severe Septic Shock Patients? Methylene Blue or Terlipressin

NCT03038503 is registered in ClinicalTrials.gov with Ramathibodi Hospital as lead sponsor.

NCT NCT03038503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03038503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
What Should be the Next Vasopressor for Severe Septic Shock Patients? Methylene Blue or Terlipressin
Lead sponsor
Ramathibodi Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2016
Completion date
December 31, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory shock, septic shock